Tandem Diabetes Care Gains FDA Clearance for Tubeless Insulin System
The FDA cleared Tandem Mobi, the company’s tubeless automated insulin delivery system. Tandem shares rose 12% to $19.62 in Friday morning trading.
By Elias SchisgallShares of Tandem Diabetes Care rose after the diabetes technology company said the Food and Drug Administration had cleared its tubeless Tandem Mobi automated insulin delivery system.Shares rose 12% to $19.62 in Friday morning trading. Despite the intraday gains, the stock remains…